Idiopathic Pulmonary Fibrosis News and Research

RSS
Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
Researchers develop gene therapy for idiopathic pulmonary fibrosis

Researchers develop gene therapy for idiopathic pulmonary fibrosis

Researchers use gene therapy that lengthens telomeres to cure pulmonary fibrosis in mice

Researchers use gene therapy that lengthens telomeres to cure pulmonary fibrosis in mice

IPF Catalyst Challenge recognizes Owlstone Medical’s Breath Biopsy platform

IPF Catalyst Challenge recognizes Owlstone Medical’s Breath Biopsy platform

Reduced activity of transcription factor plays key role in triggering pulmonary fibrosis

Reduced activity of transcription factor plays key role in triggering pulmonary fibrosis

Study identifies molecular pathway critical to development of fibrosis

Study identifies molecular pathway critical to development of fibrosis

Health scientists uncover gene linked to lung fibrosis

Health scientists uncover gene linked to lung fibrosis

Study: 52-gene risk profile accurately predicts survival for patients with severe lung disease

Study: 52-gene risk profile accurately predicts survival for patients with severe lung disease

Detailed understanding of ‘one of the most complex organs’ could provide new ways to treat lung disorders

Detailed understanding of ‘one of the most complex organs’ could provide new ways to treat lung disorders

Cellular aging process can promote idiopathic pulmonary fibrosis

Cellular aging process can promote idiopathic pulmonary fibrosis

Researchers develop potential stem cell treatment for several lung conditions

Researchers develop potential stem cell treatment for several lung conditions

New survey reveals emotional, practical challenges facing people with idiopathic pulmonary fibrosis

New survey reveals emotional, practical challenges facing people with idiopathic pulmonary fibrosis

Targeting immune cells could lead to new treatments for pulmonary fibrosis

Targeting immune cells could lead to new treatments for pulmonary fibrosis

Study identifies two T cell biomarkers that may predict survival trajectory of IPF patients

Study identifies two T cell biomarkers that may predict survival trajectory of IPF patients

CUMC researchers create new organoids that mimic features of full-sized lung

CUMC researchers create new organoids that mimic features of full-sized lung

Researcher examines scarring process in hope of preventing chronic lung transplant rejection

Researcher examines scarring process in hope of preventing chronic lung transplant rejection

Two thirds of IPF patients report being involved during the decision-making process for the most appropriate treatment

Two thirds of IPF patients report being involved during the decision-making process for the most appropriate treatment

Mayo Clinic study finds link between biology of aging and idiopathic pulmonary fibrosis

Mayo Clinic study finds link between biology of aging and idiopathic pulmonary fibrosis

Pulmospheres could serve as personalized, predictive model for assessing effect of IPF drugs

Pulmospheres could serve as personalized, predictive model for assessing effect of IPF drugs

Increasing idiopathic pulmonary fibrosis research

Increasing idiopathic pulmonary fibrosis research

Nanoparticle exposure can trigger dormant viruses in lung tissue cells

Nanoparticle exposure can trigger dormant viruses in lung tissue cells